Clinical Trial Search

Primary: Acute Toxicity Rate — 6 percentage of participants

Primary: Progression-Free Survival — 64.7 percentage of patients

Primary: Number of Patients With Venous Thromboembolism at Week 4 — 0 Participants

Primary: Patient Reported Satisfaction — 54; 55 satisfaction score at baseline

Primary: Mean Doses Given — 93.9; 63.2; 58.63 Gy

Primary: Maximum Tolerated Dose of Integrated Boost Radiation Therapy, Administered With IMRT Technique With Concurrent Chemotherapy (Cisplatin). — 70 Gray (Gy)

Primary: Recruitment Rate (Percentage of Potentially Eligible Participants Who Were Enrolled to the Study) — 20.3 percentage of participants

Primary: Toxicity Rates of Patients Treated With Concurrent Avastin and Daily Pelvic Radiation With no Other Concurrent Chemotherapy — 766 Events

Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants

Primary: Patients With Changes in Bone Marrow Assessed Through Images — 0; 4 Participants

Primary: Feasibility - Enrollment — 32 Participants

Primary: Recurrence-Free Survival — 58.1; 55.6 percentage of patients

Primary: Dose Limiting Toxicity (DLT) — 8; 23; 2 participants

Primary: Rate of Detectable Peritoneal Metastases — 0; 2 percentage of lesions

Primary: Correlation Between Circulating Levels of These Markers and Demographic Characteristics. — 39; 42; 11; 8 Participants — p=0.026

Primary: Human Papilloma Virus (HPV) Vaccine #1 Acceptance — 13; 12; 7; 3 Participants

Primary: Rate of Genetic Counseling and Testing Uptake. — 18; 15; 7; 12 Participants

Primary: Feasibility of Electronic Capture of Patient-reported Symptoms From Home Following Major Gynecologic Cancer Surgery — 18; 3; 2; 1 Participants

Primary: Change in Tumor Immune Infiltrates as Measured by PD-L1 Modified H-Score — 13.2 score on a scale

Primary: Overall Response Rate (ORR) — 0; 0 participants

Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients

Primary: Number of Participants Experiencing Dose Limiting Toxicity (DLT) Events — 0; 0; 0 Participants

Primary: Number of Seroconverted Subjects for Anti-human Papillomavirus (HPV)-16 and 18 Antibodies — 130; 4; 190; 5 Participants

Primary: Purchase Behaviours (Purchase of Items) — 3.2; 2.0; 5.9; 4.3 number of items purchased — p=<0.001

Primary: Incidence of the Composite Endpoint of Human Papillomavirus (HPV) 16/18-related Cervical Intraepithelial Neoplasia (CIN) 2 or Worse in the Base Study — 0.0; 0.4…

Primary: Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis — 27; 11 Participants

Primary: Estimate the Sensitivity of the Sentinel Lymph Node — 418 Participants

Primary: The Cystostatic, Anti-tumor Activity of the Combination of Gleevec and Gemzar Via Progression-free Survival for at Least Six Months in Patients With Recurrent or…

Primary: Number of Patients With Measurable Concentration of Gemcitabine in Uterine Vein (dFdC) — 5 Participants

Primary: Progression-free Survival — 2.9; 5.3 months — p=0.019